fasudil has been researched along with Breast Neoplasms in 5 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was conducted to develop novel fasudil derivatives after incorporation of substituted thiazoles as potent anti-breast cancer (BC) agents." | 8.02 | Design and development of novel fasudil derivatives as potent antibreast cancer agent that improves intestinal flora and intestinal barrier function in rats. ( Fu, A; Huang, R; Liang, J; Tang, M; Wang, L; Zhou, J, 2021) |
| "This study was conducted to develop novel fasudil derivatives after incorporation of substituted thiazoles as potent anti-breast cancer (BC) agents." | 4.02 | Design and development of novel fasudil derivatives as potent antibreast cancer agent that improves intestinal flora and intestinal barrier function in rats. ( Fu, A; Huang, R; Liang, J; Tang, M; Wang, L; Zhou, J, 2021) |
| "Injected human leukemic and breast cancer cells exhibited cell-type specific patterns of intravascular distribution with leukemic cells moving faster than breast cancer cells." | 1.56 | Long-term in vivo imaging reveals tumor-specific dissemination and captures host tumor interaction in zebrafish xenografts. ( Asokan, N; Bernas, SN; Bornhäuser, M; Brand, M; Daetwyler, S; Huisken, J; Kempermann, G; Lambert, K; Schmied, C; Vogler, S; Wermke, M; Wobus, M, 2020) |
| "Fasudil has been approved for the treatment of cerebral vasospasm and associated cerebral ischemic symptoms." | 1.33 | The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. ( Alicke, B; Biroc, SL; Dinter, H; Kamata, Y; Li, WW; Ohashi, Y; Okada, T; Pagila, R; Xuan, JA; Ying, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, J | 1 |
| Tang, M | 1 |
| Wang, L | 1 |
| Huang, R | 1 |
| Fu, A | 1 |
| Zhou, J | 1 |
| Asokan, N | 1 |
| Daetwyler, S | 1 |
| Bernas, SN | 1 |
| Schmied, C | 1 |
| Vogler, S | 1 |
| Lambert, K | 1 |
| Wobus, M | 1 |
| Wermke, M | 1 |
| Kempermann, G | 1 |
| Huisken, J | 1 |
| Brand, M | 1 |
| Bornhäuser, M | 1 |
| Gogebakan, B | 1 |
| Bayraktar, R | 1 |
| Suner, A | 1 |
| Balakan, O | 1 |
| Ulasli, M | 1 |
| Izmirli, M | 1 |
| Oztuzcu, S | 1 |
| Camci, C | 1 |
| Ma, L | 1 |
| Liu, YP | 1 |
| Zhang, XH | 1 |
| Xing, LX | 1 |
| Wang, JL | 1 |
| Geng, CZ | 1 |
| Ying, H | 1 |
| Biroc, SL | 1 |
| Li, WW | 1 |
| Alicke, B | 1 |
| Xuan, JA | 1 |
| Pagila, R | 1 |
| Ohashi, Y | 1 |
| Okada, T | 1 |
| Kamata, Y | 1 |
| Dinter, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for fasudil and Breast Neoplasms
| Article | Year |
|---|---|
Design and development of novel fasudil derivatives as potent antibreast cancer agent that improves intestinal flora and intestinal barrier function in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Agents; Breast Neoplasms; Col | 2021 |
Long-term in vivo imaging reveals tumor-specific dissemination and captures host tumor interaction in zebrafish xenografts.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Tra | 2020 |
Do fasudil and Y-27632 affect the level of transient receptor potential (TRP) gene expressions in breast cancer cell lines?
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Breast Neoplasms; Cell Line, Tumor; Female; H | 2014 |
Effect of RhoA signaling transduction on expression of Ezrin in breast cancer cell lines.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Blotting, Western; Breast Neoplasms; Cell Line, Tumor | 2009 |
The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Breast Neoplasms; Cell Adhesion; Cell Growth | 2006 |